277 related articles for article (PubMed ID: 25115398)
1. Fructose-2,6-bisphosphate synthesis by 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 4 (PFKFB4) is required for the glycolytic response to hypoxia and tumor growth.
Chesney J; Clark J; Klarer AC; Imbert-Fernandez Y; Lane AN; Telang S
Oncotarget; 2014 Aug; 5(16):6670-86. PubMed ID: 25115398
[TBL] [Abstract][Full Text] [Related]
2. Regulation of glucose metabolism by 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatases in cancer.
Yalcin A; Telang S; Clem B; Chesney J
Exp Mol Pathol; 2009 Jun; 86(3):174-9. PubMed ID: 19454274
[TBL] [Abstract][Full Text] [Related]
3. Small molecule inhibition of 6-phosphofructo-2-kinase suppresses t cell activation.
Telang S; Clem BF; Klarer AC; Clem AL; Trent JO; Bucala R; Chesney J
J Transl Med; 2012 May; 10():95. PubMed ID: 22591674
[TBL] [Abstract][Full Text] [Related]
4. 6-Phosphofructo-2-kinase/fructose-2,6-biphosphatase 4 is essential for p53-null cancer cells.
Ros S; Flöter J; Kaymak I; Da Costa C; Houddane A; Dubuis S; Griffiths B; Mitter R; Walz S; Blake S; Behrens A; Brindle KM; Zamboni N; Rider MH; Schulze A
Oncogene; 2017 Jun; 36(23):3287-3299. PubMed ID: 28092678
[TBL] [Abstract][Full Text] [Related]
5. Transforming growth factor β1 upregulates 6-phosphofructo-2-kinase/fructose 2,6-bisphosphatase-4 expression in A549 and MCF-10A cells.
Altunok TH; Muchut RJ; Iglesias AA; Yalcin A
Cell Biochem Funct; 2023 Dec; 41(8):1220-1229. PubMed ID: 37707291
[TBL] [Abstract][Full Text] [Related]
6. Phosphorylation of the 6-phosphofructo-2-kinase/fructose 2,6-bisphosphatase/PFKFB3 family of glycolytic regulators in human cancer.
Bando H; Atsumi T; Nishio T; Niwa H; Mishima S; Shimizu C; Yoshioka N; Bucala R; Koike T
Clin Cancer Res; 2005 Aug; 11(16):5784-92. PubMed ID: 16115917
[TBL] [Abstract][Full Text] [Related]
7. 6-Phosphofructo-2-kinase/fructose-2,6-biphosphatase 3 and 4: A pair of valves for fine-tuning of glucose metabolism in human cancer.
Yi M; Ban Y; Tan Y; Xiong W; Li G; Xiang B
Mol Metab; 2019 Feb; 20():1-13. PubMed ID: 30553771
[TBL] [Abstract][Full Text] [Related]
8. Ras transformation requires metabolic control by 6-phosphofructo-2-kinase.
Telang S; Yalcin A; Clem AL; Bucala R; Lane AN; Eaton JW; Chesney J
Oncogene; 2006 Nov; 25(55):7225-34. PubMed ID: 16715124
[TBL] [Abstract][Full Text] [Related]
9. 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase and tumor cell glycolysis.
Chesney J
Curr Opin Clin Nutr Metab Care; 2006 Sep; 9(5):535-9. PubMed ID: 16912547
[TBL] [Abstract][Full Text] [Related]
10. PFKFB2 regulates glycolysis and proliferation in pancreatic cancer cells.
Ozcan SC; Sarioglu A; Altunok TH; Akkoc A; Guzel S; Guler S; Imbert-Fernandez Y; Muchut RJ; Iglesias AA; Gurpinar Y; Clem AL; Chesney JA; Yalcin A
Mol Cell Biochem; 2020 Jul; 470(1-2):115-129. PubMed ID: 32415418
[TBL] [Abstract][Full Text] [Related]
11. Mutant studies of phosphofructo-2-kinases do not reveal an essential role of fructose-2,6-bisphosphate in the regulation of carbon fluxes in yeast cells.
Müller S; Zimmermann FK; Boles E
Microbiology (Reading); 1997 Sep; 143 ( Pt 9)():3055-3061. PubMed ID: 9308187
[TBL] [Abstract][Full Text] [Related]
12. 6-Phosphofructo-2-kinase (PFKFB3) promotes cell cycle progression and suppresses apoptosis via Cdk1-mediated phosphorylation of p27.
Yalcin A; Clem BF; Imbert-Fernandez Y; Ozcan SC; Peker S; O'Neal J; Klarer AC; Clem AL; Telang S; Chesney J
Cell Death Dis; 2014 Jul; 5(7):e1337. PubMed ID: 25032860
[TBL] [Abstract][Full Text] [Related]
13. Targeting the sugar metabolism of tumors with a first-in-class 6-phosphofructo-2-kinase (PFKFB4) inhibitor.
Chesney J; Clark J; Lanceta L; Trent JO; Telang S
Oncotarget; 2015 Jul; 6(20):18001-11. PubMed ID: 26221874
[TBL] [Abstract][Full Text] [Related]
14. Estradiol stimulates glucose metabolism via 6-phosphofructo-2-kinase (PFKFB3).
Imbert-Fernandez Y; Clem BF; O'Neal J; Kerr DA; Spaulding R; Lanceta L; Clem AL; Telang S; Chesney J
J Biol Chem; 2014 Mar; 289(13):9440-8. PubMed ID: 24515104
[TBL] [Abstract][Full Text] [Related]
15. Expression of PFKFB3 and Ki67 in lung adenocarcinomas and targeting PFKFB3 as a therapeutic strategy.
Li X; Liu J; Qian L; Ke H; Yao C; Tian W; Liu Y; Zhang J
Mol Cell Biochem; 2018 Aug; 445(1-2):123-134. PubMed ID: 29327288
[TBL] [Abstract][Full Text] [Related]
16. Functional metabolic screen identifies 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 4 as an important regulator of prostate cancer cell survival.
Ros S; Santos CR; Moco S; Baenke F; Kelly G; Howell M; Zamboni N; Schulze A
Cancer Discov; 2012 Apr; 2(4):328-43. PubMed ID: 22576210
[TBL] [Abstract][Full Text] [Related]
17. The proinflammatory mediator macrophage migration inhibitory factor induces glucose catabolism in muscle.
Benigni F; Atsumi T; Calandra T; Metz C; Echtenacher B; Peng T; Bucala R
J Clin Invest; 2000 Nov; 106(10):1291-300. PubMed ID: 11086030
[TBL] [Abstract][Full Text] [Related]
18. Metabolic enzyme PFKFB4 activates transcriptional coactivator SRC-3 to drive breast cancer.
Dasgupta S; Rajapakshe K; Zhu B; Nikolai BC; Yi P; Putluri N; Choi JM; Jung SY; Coarfa C; Westbrook TF; Zhang XH; Foulds CE; Tsai SY; Tsai MJ; O'Malley BW
Nature; 2018 Apr; 556(7700):249-254. PubMed ID: 29615789
[TBL] [Abstract][Full Text] [Related]
19. Small-molecule inhibition of 6-phosphofructo-2-kinase activity suppresses glycolytic flux and tumor growth.
Clem B; Telang S; Clem A; Yalcin A; Meier J; Simmons A; Rasku MA; Arumugam S; Dean WL; Eaton J; Lane A; Trent JO; Chesney J
Mol Cancer Ther; 2008 Jan; 7(1):110-20. PubMed ID: 18202014
[TBL] [Abstract][Full Text] [Related]
20. Nuclear targeting of 6-phosphofructo-2-kinase (PFKFB3) increases proliferation via cyclin-dependent kinases.
Yalcin A; Clem BF; Simmons A; Lane A; Nelson K; Clem AL; Brock E; Siow D; Wattenberg B; Telang S; Chesney J
J Biol Chem; 2009 Sep; 284(36):24223-32. PubMed ID: 19473963
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
